Viscogliosi Brothers to purchase Bioventus' BMP development program: 5 insights


Bioventus entered into a definitive agreement to divest its bone morphogenetic protein development program to a new Viscogliosi Brothers company.

Here are five things to know:

1. The transaction is expected to close late in the third quarter; it is conditional on Viscogliosi Brothers raising the necessary funds to complete the sale.

2. When the sale is completed, Bioventus will receive an equity stake in the new company formed by Viscogliosi Brothers that will work on the BMP program. Bioventus will also have an observational board seat to follow the company's progress on the BMP program.

3. The sale price was not disclosed.

4. Bioventus acquired the exclusive, worldwide license to the BMP portfolio from Pfizer in 2013. The portfolio includes the next-generation BMP in development, as well as a BMP program for soft tissue indications.

5. Viscogliosi Brothers is a private equity investment firm focused on the orthopedic industry.

More articles on biologics:

3 things to know about Ortho RTi

23 developments in spine & orthopedic biologics research in 2018

3 things to know about AlloSource

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers